XMTR · Xometry, Inc. · Stock research

Current Thesis

Xometry runs an AI-native marketplace for on-demand manufacturing CNC machining, sheet metal, 3D printing, injection molding pairing buyers to a global supplier network through an instant-quoting and manufacturability engine. The fundamental leg is accelerating: Q1 2026 (reported 2026-05-07) delivered marketplace revenue +40% YoY with the full-year guide raised, and Siemens agreed to embed Xometry's sourcing/pricing intelligence into Xcelerator while buying ~$50M of Class A stock. The price story that fractured on the 2026-06-02 secondary has since repaired the $85 offer level was reclaimed and the name ran to $94.37 (2026-06-26), roughly 5.5% under the $99.86 52-week high. The read that changed this week: Wedbush assumed coverage at Outperform with a $126 target (2026-07-16), reopening Street upside above spot after the stock had spent June trading at or through the analyst cluster. What is left is an accelerating narrative trading extended, now with a fresh above-price target, into a Q2 print due ~2026-08-06.

Bullish and bearish views on Xometry, Inc.

The model's bull view on Xometry, Inc. (XMTR), in brief: Wedbush assumed at Outperform, $126 PT (2026-07-16) a Street mark ~34% above the last print near $94, reversing the June setup where the stock sat above nearly every published target and resetting fresh-money asymmetry. The bear view: The 2026-06-02 secondary priced into the high. Both cases follow in full.

Bull Case

• Wedbush assumed at Outperform, $126 PT (2026-07-16) a Street mark ~34% above the last print near $94, reversing the June setup where the stock sat above nearly every published target and resetting fresh-money asymmetry.
• Q1 2026 (2026-05-07): revenue $205.1M, +36% YoY; marketplace revenue $191.3M, +40% YoY growth is accelerating off already-elevated comps. Gross profit $78.5M (+39% YoY); Adj. EBITDA $10.5M vs roughly breakeven a year prior.
• FY2026 guide raised (2026-05-07) to 27–28% revenue growth from "at least 21%," carrying ≥20% incremental Adj. EBITDA margin the operating-leverage inflection is now guided, not hoped for.
• Q2 2026 guide (2026-05-07): revenue $214–216M (+32–33% YoY), Adj. EBITDA $11–12M vs $3.9M in Q2 2025 EBITDA guided to roughly triple year-over-year.
• Siemens partnership (2026-05-07): Xometry's manufacturability/pricing/sourcing AI is embedded into Siemens Xcelerator and Siemens is buying ~$50M of stock an industrial anchor and distribution channel that validates the AI-manufacturing frame.
• Network compounding (as of 2026-03-31): active buyers 85,581 (+20% YoY); accounts with $50K+ LTM spend 1,864 (+21% YoY) the enterprise cohort is growing faster than the base.
• Product surface expanding between prints (2026-06-18): injection-molding catalogue extended with auto-quoting for glass-filled Nylon, PBT, PC-PBT, PLA, PPE-PS and PSU, plus on-platform design-for-manufacturability consultations.

Bear Case

• The 2026-06-02 secondary priced into the high. 2,647,059 shares at $85 (~$215M net, +$33.75M greenshoe) raised at the top of a 3x run capital taken when the multiple was richest, and a reminder management views these levels as a place to sell equity.
• Even after Wedbush, the target dispersion is wide. A widely-followed fair-value read sits ~$62.33 (calling the stock ~29% rich); several shops trimmed toward ~$55–65; the bullish cluster (Citi $98, Citizens $100, RBC $85) blends near $89. The $126 is the outlier, not the consensus.
• Thin-margin marketplace at a software multiple. Q1 marketplace gross margin was 34.7%; on a ~$5B market cap (~6x forward sales) a deceleration below ~30% marketplace growth compresses the multiple quickly.
• Late-stage crowd markers. Cramer called it "growing like a weed" (2026-05-21) and Benzinga flagged it overbought the same day near the $99.86 high mainstream coverage clusters at the top of a move, not the start of one.
• The next 30 days carry a binary. With the Q2 print due ~2026-08-06 and no dated catalyst before it, the tape between here and the report is a drift into earnings risk rather than a fresh accelerant.

Setup & Price Structure

The structure that broke on the June secondary has repaired. The $85 offer price acted as overhead supply through early June, then flipped: price reclaimed it and recovered ~+19% off the early-June ~$79 low to $94.37 (2026-06-26), higher in 7 of the last 10 sessions into that mark. That makes $85 the working pivot the level the reclaim is built on with the June low near $79 as the structural floor beneath it. Overhead, $99.86 (the 52-week high) is the immediate resistance; a clear break there opens the gap toward the new $126 marker. The tape is extended: the name trades within a few percent of its high, above the blended analyst cluster, and the cleanest re-accumulation entry (a higher low above $79 plus the $85 — reclaim) has already resolved. That leaves a momentum name where strength is the setup but the risk/reward for a chase at the high is narrower than it was at the reclaim.

Catalyst Calendar (next 30 days)

• ~2026-08-06 (est.) Q2 2026 earnings. The single binary in the window, ~19 days out. Guide: revenue $214–216M (+32–33% YoY), Adj. EBITDA $11–12M vs $3.9M in Q2 2025. A beat-and-raise on marketplace growth and margin sustains the re-rate; an in-line print with decelerating marketplace growth is the risk.

Elapsed catalysts

• 2026-07-16 Wedbush assumed coverage at Outperform, $126 (already printed). Watch for follow-on Street revisions; the June cluster (Citi/Citizens/RBC and the ~$62 fair-value read) is now stale versus price and may re-mark. _(passed 3d ago)_
• Greenshoe 30-day option (~2026-07-02) already elapsed. The over-allotment window from the June secondary has closed; no fresh dilution overhang from that facility remains. _(passed 17d ago)_
• No other dated catalysts before the print; product-catalogue expansions (e.g., 2026-06-18 injection molding) land undated between reports. _(passed 31d ago)_

What Would Change Our Mind

The thesis is intact while the June repair holds. It breaks on a weekly close below $79, which forfeits the early-June secondary low and, by extension, the reclaimed $85 offer shelf evidence the post-offering base failed rather than paused. A softer degrade: the Q2 print showing marketplace growth decelerating below ~30% YoY, which would compress a ~6x-sales multiple regardless of the price tape. The narrative-side condition is the small-cap-ai-momentum theme rolling to SATURATED breadth in the consumer-fintech/small-cap-AI basket thinning while headline coverage stays loud which would turn the melt-up backdrop from tailwind to headwind. Absent those, an accelerating, above-guide compounder trading near its high is behaving the way the theme is meant to; the invalidation is the $79 weekly close, not the extension itself.

Correlation Notes

Xometry trades inside the small-cap-ai-momentum basket, where breadth (7 peers +30% over three months) and ~1.8x volume participation have marked real theme demand rather than a single-name squeeze. Its highest-beta correlates are the risk-on consumer/growth cohort led by profitability-inflection names (BNPL/neobank and high-growth digital platforms), so the position rises and falls with the melt-up regime as much as with company news. A second, more idiosyncratic correlation runs through the reshoring/industrial-automation channel the Siemens embed ties XMTR to industrial capex and on-shore manufacturing sentiment, which can decouple it from the pure small-cap-AI trade on days when industrials lead. Net: expect amplified moves in both directions versus the tape, with the August print as the event that can break correlation and force the name to trade on its own numbers.